Please login to the form below

paclitaxel

This page shows the latest paclitaxel news and features for those working in and with pharma, biotech and healthcare.

Tecentriq combo fails in advanced triple negative breast cancer

Tecentriq plus paclitaxel failed to improve progression-free survival. Roche’s hopes of extending its PD-L1 inhibitor Tecentriq into metastatic triple negative breast cancer (TNBC) have fallen flat after the ... The phase 3 Impassion131 study evaluated

Latest news

Tecentriq misses the mark in advanced ovarian cancer

The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
Immutep slumps on latest efti data in breast cancer

specifically paclitaxel. ... That could suggest the effect of efti is enhanced by some property of chemo, such as increased inflammation during treatment with paclitaxel.
AZ’s comeback drug cediranib stumbles in phase 3 trial

Last year, Lynparza plus cediranib also failed to show a statistically significant improvement over standard chemotherapy with paclitaxel in patients with platinum-resistant ovarian cancer in the BAROCCO study, which included
BMS scores first oesophageal cancer nod for Opdivo in Japan

The MHLW approved Opdivo based on the results from the phase 3 ATTRACTION-3 trial, which evaluated the PD-1 inhibitor versus chemotherapy – docetaxel or paclitaxel – as a treatment for patients
Merck chases Roche with triple-negative breast cancer data for Keytruda

The actual progression-free survival (PFS) numbers for KEYNOTE-355 – which compared Keytruda plus Bristol-Myers Squibb/Celgene’s Abraxane (nab-paclitaxel), paclitaxel or gemcitabine/carboplatin to the chemo drugs given

More from news
Approximately 9 fully matching, plus 118 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

An FDA ruling on Tecentriq in combination with carboplatin and nab-paclitaxel (Abraxane) as a first-line treatment for patients with metastatic non-squamous NSCLC (based on the IMpower130 trial) is
Pharma deals in May 2015

Sorrento (Igdrasol)/ NantPharma. Asset acquisition. Acquisition of Igdrasol including Cynviloq (paclitaxel nanoparticle).
The rise of chronic disease in BRIC markets

For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

BMS appoints oncology development head

Dr Namouni first joined Bristol-Myers Squibb in France in 1999 as a life-cycle manager for chemotherapy drug Taxol (paclitaxel) and has since held a number of increasingly senior positions

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

World Ovarian Cancer Day: Current treatments and future hopes for ovarian cancer

Current chemotherapy treatment options for ovarian cancer are fairly standard. After debulking surgery, the patient will undergo their first line of chemotherapy; the standard of care involves a combination of paclitaxel

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....